Item 2.01.
Completion of Acquisition or Disposition of Assets.
On December 14, 2018, Northwest Biotherapeutics, Inc. (the Company) completed the transactions with Huawei Technologies Research & Development (UK) Limited, an unrelated third party, involving the Companys UK property: the sale of most of the property for approximately $47.3 million in gross proceeds, the retention of the Companys ownership of 17 acres of the property, which the Company believes will have substantial additional value in the future, and the lease-back of the 87,000 square foot manufacturing facility which the Company has been developing on the property, together with adjacent areas, for up to 40 years (in two 20-year terms) on favorable terms.
